Ambrilia Biopharma Inc. (TSX: AMB), a biopharmaceutical company developing innovative therapeutics in the fields of oncology and infectious diseases, announced today that it's President and Chief Executive Officer, Hans J. Mader, will present an overview of the Company at the UBS Global Life Sciences Conference to be held in New-York from September 25th to September 28th. This presentation will take place on Monday, September 25th, at 11:00 a.m. local time, in Ballroom E.
